We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
-4.59%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$99.1M
AUM Growth
-$6.37M
(-6%)
Cap. Flow
+$1.03M
Cap. Flow
% of AUM
1.04%
Top 10 Holdings %
Top 10 Hldgs %
58.86%
Holding
65
New
16
Increased
6
Reduced
7
Closed
6
Avg Time Held
2.8
quarters
Top 10 Avg Time Held
3.6
quarters
Top 20 Avg Time Held
2.7
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
|
+$3.23M |
| 2 |
OCRX
Ocera Therapeutics, Inc.
OCRX
|
+$2.97M |
| 3 |
AERI
Aerie Pharmaceuticals
AERI
|
+$2.87M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$1.54M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$989K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMPE
Ampio Pharmaceuticals Inc.
AMPE
|
+$7.02M |
| 2 |
Vaxart
VXRT
|
+$2.08M |
| 3 |
Arcturus Therapeutics
ARCT
|
+$1.47M |
| 4 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
+$1.42M |
| 5 |
Eocene Ltd. Ordinary Shares
EOCN
|
+$678K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.58% |
| 2 | Miscellaneous | 24.32% |
| 3 | Financials | 1.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
PCYC
1
DELISTED
PHARMACYCLICS INC
PCYC
| $13M | 13.14% |
110,928
-4,700
| -4% | -$536K |
2013 Q2
5 quarters
|
|
2
DELISTED
Windtree Therapeutics Inc
WINT
| $10.5M | 10.58% |
407,053
| – | – |
2013 Q2
5 quarters
|
|
3
AtriCure
ATRC
$2.89B
| $8.82M | 8.89% |
598,883
+27,896
| +5% | +$444K |
2013 Q2
5 quarters
|
|
|
NXTM
4
DELISTED
NxStage Medical Inc.
NXTM
| $5.04M | 5.09% |
384,154
| – | – |
2013 Q2
5 quarters
|
|
5
Insulet
PODD
$9.58B
| $4.03M | 4.07% |
109,418
| – | – |
2013 Q2
5 quarters
|
|
|
ASPX
6
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
| $3.9M | 3.94% |
+152,002
| New | +$3.23M |
2014 Q3
0 quarters
|
|
7
DELISTED
Novadaq Technologies Inc.
NVDQ
| $3.34M | 3.37% |
263,541
| – | – |
2013 Q2
5 quarters
|
|
|
OCRX
8
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $3.31M | 3.34% |
675,650
+515,028
| +321% | +$2.97M |
2013 Q3
4 quarters
|
|
|
DSCI
9
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $3.21M | 3.23% |
384,794
| – | – |
2013 Q2
5 quarters
|
|
10
Stereotaxis
STXS
$106M
| $3.19M | 3.22% |
1,718,719
-8,106
| -0.5% | -$19.4K |
2013 Q2
5 quarters
|
|
11
Protalix BioTherapeutics
PLX
$222M
| $3.12M | 3.14% |
128,844
+11,000
| +9% | +$317K |
2013 Q2
5 quarters
|
|
|
AERI
12
DELISTED
Aerie Pharmaceuticals
AERI
| $3.01M | 3.03% |
+145,342
| New | +$2.87M |
2014 Q3
0 quarters
|
|
|
BSTC
13
DELISTED
BioSpecifics Technologies Corp.
BSTC
| $2.12M | 2.14% |
60,054
-10,034
| -14% | -$295K |
2013 Q2
5 quarters
|
|
14
DELISTED
Molecular Templates, Inc.
MTEM
| $2.01M | 2.02% |
3,369
+987
| +41% | +$683K |
2013 Q4
3 quarters
|
|
|
CLVS
15
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.67M | 1.69% |
+36,900
| New | +$1.54M |
2014 Q3
0 quarters
|
|
|
CRDC
16
DELISTED
CARDICA INC COM NEW (DE)
CRDC
| $1.59M | 1.6% |
148,600
| – | – |
2013 Q2
5 quarters
|
|
17
DELISTED
BioTelemetry, Inc.
BEAT
| $1.58M | 1.59% |
235,645
| – | – |
2013 Q2
5 quarters
|
|
|
XNPT
18
DELISTED
XENOPORT, INC.
XNPT
| $1.29M | 1.3% |
240,190
| – | – |
2013 Q2
5 quarters
|
|
|
UPI
19
DELISTED
UROPLASTY INC-NEW
UPI
| $1.22M | 1.23% |
486,062
+44,203
| +10% | +$115K |
2013 Q2
5 quarters
|
|
|
SPNC
20
DELISTED
Spectranetics Corp
SPNC
| $1.12M | 1.13% |
42,162
| – | – |
2013 Q2
5 quarters
|
|
21
Riot Platforms
RIOT
$6.26B
| $1.09M | 1.1% |
82,250
| – | – |
2013 Q2
5 quarters
|
|
|
22
Neurocrine Biosciences
NBIX
$13.7B
| $1.04M | 1.04% |
+66,141
| New | +$989K |
2014 Q3
0 quarters
|
|
|
23
Eocene Ltd. Ordinary Shares
EOCN
$3.39M
| $1.01M | 1.01% |
81
-62
| -43% | -$678K |
2014 Q1
2 quarters
|
|
24
Johnson & Johnson
JNJ
$599B
| $1M | 1.01% |
9,400
| – | – |
2013 Q2
5 quarters
|
|
|
ECI
25
DELISTED
ENCISION INC
ECI
| $983K | 0.99% |
1,062,500
| – | – |
2014 Q2
1 quarter
|
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q3 2014 Portfolio in Review
As of Q3 2014, DAFNA Capital Management held 65 positions worth $99.1M, down 6% from $106M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
DAFNA Capital Management's Q3 2014 filing shows 16 new, 6 increased, 7 reduced and 6 closed positions. Its largest new stake was AUSPEX PHARMACEUTICALS INC COM STK (DE): 152,002 shares worth $3.9M. The largest sale was Ampio Pharmaceuticals Inc., an estimated $7.02M.
By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 82% a quarter earlier, followed by Miscellaneous and Financials.
- DAFNA Capital Management's largest Q3 2014 buy was AUSPEX PHARMACEUTICALS INC COM STK (DE): 152,002 shares worth $3.9M.
- DAFNA Capital Management added most to Ocera Therapeutics, Inc. in Q3 2014, an estimated $2.97M increase.
- DAFNA Capital Management's biggest Q3 2014 reduction was Ampio Pharmaceuticals Inc., cutting an estimated $7.02M.
- DAFNA Capital Management fully exited Vaxart in Q3 2014, selling an estimated $2.08M.
- DAFNA Capital Management's ten largest holdings make up 59% of its $99.1M portfolio in Q3 2014.
- DAFNA Capital Management opened 16 new positions and closed 6 in Q3 2014.
- DAFNA Capital Management's portfolio value fell 6% quarter-over-quarter to $99.1M.
Based on DAFNA Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.